Nalmefene enhances the remyelinating ability of nalfurafine when administered therapeutically at very low doses during experimental autoimmune encephalomyelitis

Abstract Objectives Multiple sclerosis is an immune‐mediated inflammatory disease of the central nervous system. Recently, kappa opioid receptor (KOR) agonists were found to promote remyelination and recovery in models of demyelination. However, the side effects of many full KOR agonists limit clini...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Lisa Denny, Katharina Robichon, Nikki Templeton, Mackenzie Kiernan, Thomas E Prisinzano, Bronwyn M Kivell, Anne Camille La Flamme
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2025-01-01
Saila:	Clinical & Translational Immunology
Gaiak:	experimental autoimmune encephalomyelitis kappa opioid receptor agonist mu opioid receptor antagonist nalfurafine nalmefene
Sarrera elektronikoa:	https://doi.org/10.1002/cti2.70069
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!